A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients
Objectives: The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle ® , Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable.Methods: The efficacy of the stent was evaluated i...
Gespeichert in:
| Veröffentlicht in: | European urology 2000-09, Vol.38 (3), p.272-278 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 278 |
|---|---|
| container_issue | 3 |
| container_start_page | 272 |
| container_title | European urology |
| container_volume | 38 |
| creator | Traxer, Olivier Anidjar, Maurice Gaudez, François Saporta, François Daudon, Michel Cortesse, Ariane Desgrandchamps, François Cussenot, Olivier Teillac, Pierre Le Duc, Alain |
| description | Objectives: The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle ® , Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable.Methods: The efficacy of the stent was evaluated in terms of return of micturition, level of patient satisfaction, uroflowmetry and residual urine. Any stents removed were examined by infrared spectrophotometry for the presence of crystalline encrustations.Results: From December 1997 to April 1999, 20 stents were inserted under local anaesthesia in 17 patients aged 54–90 years. Stents remained in place for an average of 3.5 months. Two migrations were reported. The mean maximum flow rate was 13.7 ml/s and the mean residual urine was 110 ml. The infrared spectrophotometry study revealed a glycoprotein film on stents in place for 1–6 months, accompanied by uric acid crystals on stents in place for 9 months.Conclusion: The Trestle prostatic stent is effective and constitutes a good alternative to surgical treatment in patients with a high operative risk. |
| doi_str_mv | 10.1159/000020293 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_10940700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71797734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c4214d33e989e32f73c3cb47be17a20e2fb3fa01faa2610aac859c76081b63fb3</originalsourceid><addsrcrecordid>eNpt0MtO3DAUBmCrAsFwWXSNVFkVqsQiYPskcbIERBkk1CIu6-jEczy4ZJLUzgix6zv0Dfsk9TDDZYE3lvx_PpZ_xj5LcShlVh6JuJRQJXxiI1loSHSWizU2EiBUogooNtlWCL-igqyEDbYpRZkKLcSIVcf8Bz3yK9-FAQdn-M1A7cBt5_lwT_zWEw6zxUln-Qm1btq-s-OnnnzfYHDIXcvHbnr_78_faxce-FUE8VrYYesWm0C7q32b3X0_uz0dJ5c_zy9Ojy8TA5keEpMqmU4AqCxKAmU1GDB1qmuSGpUgZWuwKKRFVLkUiKbISqNzUcg6hxhus2_Lub3vfs8pDNXMBUNNgy1181BpqUutIY3wYAlN_EbwZKveuxn6p0qKatFm9dpmtF9WQ-f1jCbv5LK-CPZXAIPBxnpsjQtvLs0B5ILtLdkD-in51_zlla8fpmd318-g6icW_gPU0ZDT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71797734</pqid></control><display><type>article</type><title>A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients</title><source>MEDLINE</source><source>Karger Journals</source><creator>Traxer, Olivier ; Anidjar, Maurice ; Gaudez, François ; Saporta, François ; Daudon, Michel ; Cortesse, Ariane ; Desgrandchamps, François ; Cussenot, Olivier ; Teillac, Pierre ; Le Duc, Alain</creator><creatorcontrib>Traxer, Olivier ; Anidjar, Maurice ; Gaudez, François ; Saporta, François ; Daudon, Michel ; Cortesse, Ariane ; Desgrandchamps, François ; Cussenot, Olivier ; Teillac, Pierre ; Le Duc, Alain</creatorcontrib><description>Objectives: The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle ® , Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable.Methods: The efficacy of the stent was evaluated in terms of return of micturition, level of patient satisfaction, uroflowmetry and residual urine. Any stents removed were examined by infrared spectrophotometry for the presence of crystalline encrustations.Results: From December 1997 to April 1999, 20 stents were inserted under local anaesthesia in 17 patients aged 54–90 years. Stents remained in place for an average of 3.5 months. Two migrations were reported. The mean maximum flow rate was 13.7 ml/s and the mean residual urine was 110 ml. The infrared spectrophotometry study revealed a glycoprotein film on stents in place for 1–6 months, accompanied by uric acid crystals on stents in place for 9 months.Conclusion: The Trestle prostatic stent is effective and constitutes a good alternative to surgical treatment in patients with a high operative risk.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>EISSN: 1421-993X</identifier><identifier>DOI: 10.1159/000020293</identifier><identifier>PMID: 10940700</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Basel, Switzerland: Elsevier</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; BPH ; Diseases of the urinary system ; Equipment Design ; Humans ; Male ; Medical sciences ; Middle Aged ; Postoperative Complications - epidemiology ; Prostatic Hyperplasia - complications ; Prostatic Hyperplasia - surgery ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Risk Factors ; Stents - adverse effects ; Urinary Retention - etiology ; Urinary Retention - surgery</subject><ispartof>European urology, 2000-09, Vol.38 (3), p.272-278</ispartof><rights>2000 S. Karger AG, Basel</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-c4214d33e989e32f73c3cb47be17a20e2fb3fa01faa2610aac859c76081b63fb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1463310$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10940700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Traxer, Olivier</creatorcontrib><creatorcontrib>Anidjar, Maurice</creatorcontrib><creatorcontrib>Gaudez, François</creatorcontrib><creatorcontrib>Saporta, François</creatorcontrib><creatorcontrib>Daudon, Michel</creatorcontrib><creatorcontrib>Cortesse, Ariane</creatorcontrib><creatorcontrib>Desgrandchamps, François</creatorcontrib><creatorcontrib>Cussenot, Olivier</creatorcontrib><creatorcontrib>Teillac, Pierre</creatorcontrib><creatorcontrib>Le Duc, Alain</creatorcontrib><title>A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Objectives: The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle ® , Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable.Methods: The efficacy of the stent was evaluated in terms of return of micturition, level of patient satisfaction, uroflowmetry and residual urine. Any stents removed were examined by infrared spectrophotometry for the presence of crystalline encrustations.Results: From December 1997 to April 1999, 20 stents were inserted under local anaesthesia in 17 patients aged 54–90 years. Stents remained in place for an average of 3.5 months. Two migrations were reported. The mean maximum flow rate was 13.7 ml/s and the mean residual urine was 110 ml. The infrared spectrophotometry study revealed a glycoprotein film on stents in place for 1–6 months, accompanied by uric acid crystals on stents in place for 9 months.Conclusion: The Trestle prostatic stent is effective and constitutes a good alternative to surgical treatment in patients with a high operative risk.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>BPH</subject><subject>Diseases of the urinary system</subject><subject>Equipment Design</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postoperative Complications - epidemiology</subject><subject>Prostatic Hyperplasia - complications</subject><subject>Prostatic Hyperplasia - surgery</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Risk Factors</subject><subject>Stents - adverse effects</subject><subject>Urinary Retention - etiology</subject><subject>Urinary Retention - surgery</subject><issn>0302-2838</issn><issn>1873-7560</issn><issn>1421-993X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtO3DAUBmCrAsFwWXSNVFkVqsQiYPskcbIERBkk1CIu6-jEczy4ZJLUzgix6zv0Dfsk9TDDZYE3lvx_PpZ_xj5LcShlVh6JuJRQJXxiI1loSHSWizU2EiBUogooNtlWCL-igqyEDbYpRZkKLcSIVcf8Bz3yK9-FAQdn-M1A7cBt5_lwT_zWEw6zxUln-Qm1btq-s-OnnnzfYHDIXcvHbnr_78_faxce-FUE8VrYYesWm0C7q32b3X0_uz0dJ5c_zy9Ojy8TA5keEpMqmU4AqCxKAmU1GDB1qmuSGpUgZWuwKKRFVLkUiKbISqNzUcg6hxhus2_Lub3vfs8pDNXMBUNNgy1181BpqUutIY3wYAlN_EbwZKveuxn6p0qKatFm9dpmtF9WQ-f1jCbv5LK-CPZXAIPBxnpsjQtvLs0B5ILtLdkD-in51_zlla8fpmd318-g6icW_gPU0ZDT</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Traxer, Olivier</creator><creator>Anidjar, Maurice</creator><creator>Gaudez, François</creator><creator>Saporta, François</creator><creator>Daudon, Michel</creator><creator>Cortesse, Ariane</creator><creator>Desgrandchamps, François</creator><creator>Cussenot, Olivier</creator><creator>Teillac, Pierre</creator><creator>Le Duc, Alain</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients</title><author>Traxer, Olivier ; Anidjar, Maurice ; Gaudez, François ; Saporta, François ; Daudon, Michel ; Cortesse, Ariane ; Desgrandchamps, François ; Cussenot, Olivier ; Teillac, Pierre ; Le Duc, Alain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c4214d33e989e32f73c3cb47be17a20e2fb3fa01faa2610aac859c76081b63fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>BPH</topic><topic>Diseases of the urinary system</topic><topic>Equipment Design</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postoperative Complications - epidemiology</topic><topic>Prostatic Hyperplasia - complications</topic><topic>Prostatic Hyperplasia - surgery</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Risk Factors</topic><topic>Stents - adverse effects</topic><topic>Urinary Retention - etiology</topic><topic>Urinary Retention - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Traxer, Olivier</creatorcontrib><creatorcontrib>Anidjar, Maurice</creatorcontrib><creatorcontrib>Gaudez, François</creatorcontrib><creatorcontrib>Saporta, François</creatorcontrib><creatorcontrib>Daudon, Michel</creatorcontrib><creatorcontrib>Cortesse, Ariane</creatorcontrib><creatorcontrib>Desgrandchamps, François</creatorcontrib><creatorcontrib>Cussenot, Olivier</creatorcontrib><creatorcontrib>Teillac, Pierre</creatorcontrib><creatorcontrib>Le Duc, Alain</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Traxer, Olivier</au><au>Anidjar, Maurice</au><au>Gaudez, François</au><au>Saporta, François</au><au>Daudon, Michel</au><au>Cortesse, Ariane</au><au>Desgrandchamps, François</au><au>Cussenot, Olivier</au><au>Teillac, Pierre</au><au>Le Duc, Alain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>38</volume><issue>3</issue><spage>272</spage><epage>278</epage><pages>272-278</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><eissn>1421-993X</eissn><coden>EUURAV</coden><abstract>Objectives: The objective of this study was to evaluate the efficacy and safety of a new prostatic stent (Trestle ® , Boston Scientific Microvasive) for the treatment of BPH in patients with complete urinary retention and considered to be inoperable.Methods: The efficacy of the stent was evaluated in terms of return of micturition, level of patient satisfaction, uroflowmetry and residual urine. Any stents removed were examined by infrared spectrophotometry for the presence of crystalline encrustations.Results: From December 1997 to April 1999, 20 stents were inserted under local anaesthesia in 17 patients aged 54–90 years. Stents remained in place for an average of 3.5 months. Two migrations were reported. The mean maximum flow rate was 13.7 ml/s and the mean residual urine was 110 ml. The infrared spectrophotometry study revealed a glycoprotein film on stents in place for 1–6 months, accompanied by uric acid crystals on stents in place for 9 months.Conclusion: The Trestle prostatic stent is effective and constitutes a good alternative to surgical treatment in patients with a high operative risk.</abstract><cop>Basel, Switzerland</cop><pub>Elsevier</pub><pmid>10940700</pmid><doi>10.1159/000020293</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0302-2838 |
| ispartof | European urology, 2000-09, Vol.38 (3), p.272-278 |
| issn | 0302-2838 1873-7560 1421-993X |
| language | eng |
| recordid | cdi_pubmed_primary_10940700 |
| source | MEDLINE; Karger Journals |
| subjects | Aged Aged, 80 and over Biological and medical sciences BPH Diseases of the urinary system Equipment Design Humans Male Medical sciences Middle Aged Postoperative Complications - epidemiology Prostatic Hyperplasia - complications Prostatic Hyperplasia - surgery Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Risk Factors Stents - adverse effects Urinary Retention - etiology Urinary Retention - surgery |
| title | A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A04%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20New%20Prostatic%20Stent%20for%20the%20Treatment%20of%20Benign%20Prostatic%20Hyperplasia%20in%20High%E2%80%93Risk%20Patients&rft.jtitle=European%20urology&rft.au=Traxer,%20Olivier&rft.date=2000-09-01&rft.volume=38&rft.issue=3&rft.spage=272&rft.epage=278&rft.pages=272-278&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1159/000020293&rft_dat=%3Cproquest_pubme%3E71797734%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71797734&rft_id=info:pmid/10940700&rfr_iscdi=true |